Gritstone Oncology Inc diskutieren

Gritstone bio, Inc. (NASDAQ: GRTS) is now covered by analysts at B. Riley. They set a "buy" rating and a $8.00 price target on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) had its price target raised by analysts at Piper Sandler from $6.00 to $7.00. They now have an "overweight" rating on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) had its price target lowered by analysts at HC Wainwright from $7.00 to $4.00. They now have a "buy" rating on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $3.00 price target on the stock, down previously from $6.00.

Gritstone Oncology Inc. has been dealing with a class action lawsuit, which is never good news for a company. The recent articles highlight the legal troubles the company is facing, and this could weigh heavily on the stock price. While the company has some promising technology in the oncology space, the legal issues and uncertainty surrounding the business make me cautious about the stock at this time. I would wait on the sidelines until the legal situation is resolved before considering an investment. At the current price of $0.56, I believe the downside risk outweighs the potential upside, so I would rate this as a 'sell' and set a target price of $0.20. The company has a lot of work to do to regain investor confidence, and I would want to see clear signs of progress before becoming more bullish on the stock.

Gritstone Oncology Inc. has been facing a series of legal troubles, which have weighed heavily on the stock price. The company is currently embroiled in a class-action lawsuit, with several law firms reminding investors of the looming deadlines to join the lawsuit. This legal overhang creates a lot of uncertainty around the company's future, and I believe it's best to steer clear of the stock until the legal issues are resolved. The current price of $0.5415 seems too high given the risks, and I would recommend selling the stock and waiting for a clearer path forward before considering a re-entry. It's important to remember that legal battles can be unpredictable and often result in significant financial and reputational damage for the companies involved. In this case, I believe the risks outweigh the potential rewards, and it's prudent to take a step back and let the dust settle before making any investment decisions.